IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
IMMUNIC, INC. reported Q1 2026 results with $0 revenue and a net loss of $32.6M, widening from a $25.5M loss in Q1 2025. The company is advancing clinical programs, including fully enrolled Phase 3 ENSURE trials for vidofludimus calcium. Positive Phase 2 results for IMU-381 and IMU-856 were noted. R&D operations have centralized in Germany, and a key European patent was granted, extending protection into 2038. The company is exploring partnerships and licensing opportunities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments